Clinical Trials in Dermatology (PART 1)

CLINICAL TRIALS: THE NUTS, BOLTS AND UNIQUE CONSIDERATIONS FOR DERMATOLOGIC PATIENTS

Jonathan S. Weiss, MD, FAAD is an adjunct assistant clinical professor of Dermatology at the Emory University School of Medicine in Atlanta, Georgia. He is President, Co-managing partner and practices at Georgia Dermatology Partners, with four offices in metropolitan Atlanta. He performs clinical pharmacology research at Gwinnett Clinical Research Center in his Snellville office. Dr. Weiss earned his medical degree from the University of Michigan in Ann Arbor, where he also served as chief resident in the dermatology department. He maintains a full-time clinical dermatology practice and oversees an active clinical trial unit studying a wide range of dermatologic conditions and pharmaceutical compounds. Dr. Weiss has been an investigator in over 230 studies.

THE WHAT, WHY, AND HOW OF PRAGMATIC CLINICAL TRIALS

Joel M. Gelfand, MD, MSCE, FAAD is the James J. Leyden Professor of Dermatology and Epidemiology at the University of Pennsylvania Perelman School of Medicine. He is also Vice Chair of Clinical Research, Medical Director of the Dermatology Clinical Studies Unit, and Director of the Psoriasis and Phototherapy Treatment Center. He is a nationally and internationally recognized expert in psoriasis, clinical epidemiology, drug safety, and clinical trials. Dr. Gelfand is the author of over 260 scientific publications cited over 30,000 times. He is Deputy Editor of the Journal Investigative Dermatology. He is the recipient of the American Skin Association’s Psoriasis Achievement Award, the Lady Barbara Colyton’s Award for Autoimmune Research, the National Psoriasis Foundation’s scientific achievement award, and is an elected member of the American Society for Clinical Investigation. He has given over 10 named lectureships and keynote addresses including the Society for Investigative Dermatology’s Eugene M. Farber lecture and the American Academy of Dermatology’s Marion B. Sulzberger lecture. He has received grants from NIH, FDA, PCORI, and the National Psoriasis Foundation to support his independent research program. The overarching goal of his research and clinical practice is to improve psoriasis patient outcomes in the skin and joints, while lowering the risk of diabetes, CV disease and mortality.